"Having successfully confirmed a dose effect, Amorcyte looks forward to proceeding with a larger prospective randomized trial and furthering our clinical program with AMR-001," said Andrew Pecora, M.D., Chairman of the Board of Amorcyte. "These strong Phase I results, combined with proprietary innovative technologies that address the challenges of commercializing stem cell products, position us to bring to market a stem cell therapy with the potential to address a serious unmet patient need."
About Cardiovascular Disease
It is estimated that each year there are approximately 1.1 million instances of acute myocardial infarction (AMI). 160,000 AMIs are severe enough to cause ventricular remodeling leading to further tissue damage over time and downstream adverse events including premature death, recurrent myocardial infarction, congestive heart failure, significant arrhythmias and acute coronary syndrome. Amorcyte's therapy aims to limit ventricular remodeling.
About Amorcyte, Inc.
Amorcyte is a privately held biotechnology company developing cell therapy products to treat cardiovascular disease. Its lead product AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in AMI ever conducted that has prospectively established a significant relationship between dose and effect. Amorcyte has partnered with Progenitor Cell Therapy, a leading provider of clinical, manufacturing and ot
|SOURCE Amorcyte, Inc.|
Copyright©2009 PR Newswire.
All rights reserved